Hyderabad, India-headquartered Dr. Reddy’s Laboratories Ltd.’s wholly owned subsidiary, Dr. Reddy’s Laboratories SA, announced the acquisition of the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited.
The U.S. generic prescription portfolio includes approximately 45 commercial products, four pipeline products, and 40 approved non-marketed products, including a number of generic products focused on women’s health. Of the approved high-value products, there is a hormonal vaginal ring, a birth control pill and a cardiovascular product.
According to IQVIA, the American multinational company serving the combined industries of health information technology and clinical research, the total addressable market value for the pipeline and approved non-marketed products in the U.S. is approximately $3.6 billion for the calendar year ending in December 2022.
The acquisition is expected to complement Dr. Reddy’s U.S. retail prescription pharmaceutical business with products with limited competition.
Marc Kikuchi, chief executive officer, North America business, Dr. Reddy’s, said, “This important acquisition provides our North America organization with a significant foothold in the women’s health space.” According to Kikuchi, the acquisition was in line with their strategy to enhance their portfolio in their chosen growth markets. “We are well-positioned to successfully integrate the portfolio,” he added.
Last updated: December 26th, 2025
